Trial Profile
A study evaluating efficacy of of addition of third drug (Cyclophosphamide or Bortezomib) to the combination of pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Jul 2017
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Pomalidomide (Primary) ; Bortezomib; Cyclophosphamide
- Indications Multiple myeloma
- Focus Therapeutic Use
- 21 Jul 2017 New trial record
- 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association